{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-005160","form_type":"8-K","ticker":"SRPT","cik":"0000873303","company_name":"Sarepta Therapeutics, Inc.","filed_at":"2025-01-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:06.566894+00:00","generated_at":"2026-05-28T04:17:12.663905+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Sarepta reports preliminary Q4 2024 net product revenue $638.2M, FY2024 $1.79B, beating guidance by $100M+","bullets":["Preliminary total net product revenue Q4 2024 $638.2M, FY2024 $1.79B, exceeding full-year guidance by over $100M.","ELEVIDYS net product revenue Q4 2024 $384.2M (up 112% sequential), FY2024 $820.8M.","RNA-based PMO net product revenue Q4 2024 $254.0M, FY2024 $967.2M, grew YoY.","Cash, cash equivalents, and investments ~$1.5B as of Dec 31, 2024.","Reiterated 2025 full-year net product revenue guidance of $2.9-3.1B."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-005160","json":"https://secwatch.observer/filing/0001193125-25-005160.json","markdown":"https://secwatch.observer/filing/0001193125-25-005160.md","text":"https://secwatch.observer/filing/0001193125-25-005160.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/873303/000119312525005160/0001193125-25-005160-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/873303/000119312525005160/d900352d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-28T04:17:12.663905+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}